Copyright © Inderes 2011 - present. All rights reserved.

Sprint Bioscience

1.92 SEK

+3.23 %

Less than 1K followers

SPRINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+3.23 %
+15.66 %
+30.61 %
+17.43 %
+217.88 %
+37.49 %
+201.76 %
-65.98 %
-83.64 %

Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.

Read more
Market cap
202.59M SEK
Turnover
1.2M SEK
Revenue
167.17M
EBIT %
58.2 %
P/E
1.94
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.5
2026

Interim report Q1'26

13.5
2026

General meeting '26

26.8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.